



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of: Salfeld, J.G. *et al.*

Serial No.: 09/540,018

Filed: March 31, 2000

For: Human Antibodies that Bind Human
TNF α

Attorney Docket No.: BBI-043CPACN

Group Art Unit: 1644

Examiner: D. Saunders

RECEIVED

JUN 11 2002

TECH CENTER 1600/2900

Commissioner for Patents
Washington, D.C. 20231

COPY OF PAPERS
ORIGINALLY FILED


Certificate of First Class Mailing (37 CFR 1.8(a))

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on the date set forth below.

5 | 27 | 02

Date of Signature and of Mail Deposit

By:


Elizabeth A. Hanley, Esq.
Reg. No. 33,505
Attorney for Applicants

RESPONSE TO NOTICE OF NON-COMPLIANCE

Dear Sir:

This Response to Notice of Non-Compliance is submitted in response to the Office communication dated April 24, 2002 in which the Examiner points out that Applicants' response filed on February 13, 2002 failed to comply with 37 CFR 1.121, because amended claim 71 did not show underlining of what was added. A corrected version of the "Version With Markings To Show Changes" is attached hereto.